A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions. Treatment groups consisted of different combinations of dose (0, 5, or 30 µg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age). The primary endpoints were the incidence of bone neoplasms and effects on bone mass and structure as evaluated by quantitative computed tomography and histomorphometery. Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 µg/kg for 20 or 24 months. No neoplasms were found when the 5 µg/kg treatment was initiated at 6 months of age and continued for either 6 or 20 months (up to 70% of life span). This treatment regimen defined a "no-effect" dose for neoplasm formation that nevertheless resulted in substantial increases in bone mass. These results demonstrate that treatment duration and administered dose are the most important factors in the teriparatide-induced bone tumors in rats. FIGURE 1.-Modeling of clinically observed bone tumor incidence. Clinically observed bone tumor incidence during the live phase of the first oncogenicity study Vahle et al., 2002) was found to fit an exponential equation, where tumor incidence was F(x) = e A(X-Xo) with X = treatment duration, Xo = the lag phase before tumors were observed, and A = a coefficient. Observed bone tumor incidence is represented by the dots for male (M) and female (F) rats administered 5, 30, or 75 ug/kg teriparatide. The solid line represents the exponential curve, and the fit is described by the correlation coefficient R2 in the table. Bone tumors were not observed clinically for the 5 ug/kg male group (M5) or for either vehicle control group during the live phase in the original study. Correlation analysis showed the fit to be highly significant in all cases ( p < 0.001). The calculated lag phase Xo is also compared to the real Xo observed during the live phase.
INTRODUCTION
A new treatment for osteoporosis is teriparatide (rDNA origin) injection, [recombinant human parathyroid hormone (1-34)], the 34-amino acid N -terminal portion of natural human parathyroid hormone (PTH). In a variety of in vivo studies, hPTH(1-34) produced the same spectrum of skeletal responses as elicited by the native 84-amino acid hormone (Mosekilde et al., 1991; Kimmel et al., 1993; Oxlund et al., 1993; Stanislaus et al., 2000) . Once-daily administration of teriparatide by subcutaneous injection stimulated new bone formation by activating quiescent bone lining cells, by stimulating osteoblast differentiation from precursors, and by inhibiting osteoblast apoptosis, with little to no stimulation of bone resorption (Hock, 2001) . Teriparatide stimulated mineral apposition onto trabecular, endocortical, and periosteal bone surfaces in rats, monkeys, and humans, resulting in substantial increases in bone mass, improved architecture and enhanced biomechanical strength (Sato et al., 1997; Jerome et al., 1999; Burr et al., 2001; Dempster et al., 2001; Jiang et al., 2003; Zanchetta et al., 2003) . In postmenopausal women with osteoporosis, vertebral and nonvertebral fracture incidence was significantly reduced with teriparatide treatment (Neer et al., 2001) , demonstrating therapeutic efficacy. A 2-year rat carcinogenicity study showed that once-daily subcutaneous administration of teriparatide resulted in large, dose-dependent increases in bone mass, as well as bone proliferative lesions, including osteosarcoma at all dose levels tested Vahle et al., 2002) .
This previously reported study had several design features that differ from the intended short-term clinical use of teri-paratide, thus making the relevance of the rat findings difficult to assess in terms of safety for humans (Tashjian and Chabner, 2002) . Rats were treated once daily for 24 months starting at approximately 2 months of age at treatment initiation. Thus, rats were treated for nearly their entire life span (70-80% of lifetime) and during the rapid phase of longitudinal skeletal growth Tashjian and Chabner, 2002; Vahle et al., 2002) . In contrast, the intended clinical use is up to 2 years of therapy in older patients with a mature skeleton, which corresponds to approximately 2-3% of the human lifespan.
The results of the initial rat carcinogenicity study strongly suggested that the administered dose, as well as the duration of treatment, were important factors in the development of bone neoplasms. Additionally, the results of the first study raised questions about the role of age at initiation of treatment on the development of bone proliferative lesions . Therefore, a second study was conducted to clarify the relative importance of treatment duration, administered dose, and initiation of treatment during the phase of rapid skeletal growth on the development of bone neoplasms in rats. This report describes the design, results, and interpretation of the findings from the second long-term study of intact female F344 rats.
METHODS

Initial Carcinogenicity Study
The initial oncogenicity study was conducted with intact Fischer 344 female and male rats (F344, Taconic Laboratory Animals and Services, Germantown, NY) that were approximately 6 to 8 weeks of age, as described in detail previously Vahle et al., 2002) . Rats were administered 0, 5, 30, or TOXICOLOGIC PATHOLOGY IN] for 2 years. A new analysis from the first study is presented in this report that includes a statistical modeling of the incidence of clinically observed bone tumors versus time, using an exponential equation (Figure 1 ). The incidence of bone proliferative lesions observed during the live phase of the original study was analyzed using a nonlinear fixed effects model (Splus version 2000, Insightful Corporation, Seattle,  WA) .
Present Study
The second study, the primary focus of this report, used intact female F344 rats at 6 to 7 weeks of age that were randomly distributed to treatment groups (n = 30-60/group) and individually housed in ventilated stainless steel cages. Because there were no statistically significant differences between male and female rats in the initial study, only female F344 rats were used in the current study. Rats were fed Certified Rodent Diet 5002 (PmgI Nutrition International, Inc.) and tap water ad libitum. Rats were examined daily and detailed clinical observations were recorded for each rat weekly until study termination. Animal studies were conducted in accordance with federal animal care guidelines, in consultation with regulatory agencies, and approved by the Lilly Research Laboratories Institutional Animal Care and Use Committee.
This protocol included different combinations of administered dose, duration of treatment, and age at initiation of treatment, resulting in a large study with dosed groups of short-term and long-term duration ( Figure 2 ). This study involved 480 rats in 8 main groups (n = 60 per group) that were euthanized and evaluated at 26 months of age. The negative control group was given once-daily injections of vehicle from 2 to 26 months of age (group A). A positive control group of rats (group B30), identical in design to the mid-dose of the original carcinogenicity study, was given once-daily injections of 30 µg/kg from 2 to 26 months. Two groups of rats were given 5 or 30 µg/kg for 6 months; with treatment initi-FIGURE 2.-Study design summary. The duration and age of initiation at onset of treatment injections are illustrated here. The white shading represents the time before teriparatide injections when animals received only vehicle; the dark gray shading is the duration of teriparatide injections; the light gray shading represents the time after teriparatide injections were stopped and rats received vehicle injections. There were 60 rats per group. ated at 6 months of age and continued until 12 months of age (E5 and E30). In these 2 groups, rats were injected with vehicle daily both prior to and following the teriparatide treatment phase. Similarly 2 groups of rats received teriparatide doses of 5 or 30 µg/kg for 6 months, from 2 to 8 months of age (H5 and H30). In these 2 groups, rats were injected with vehicle daily from 8 to 26 months of age. In addition, 2 groups of rats were given 5 or 30 µg/kg from 6 to 26 months of age (I5 and I30). These rats were injected with vehicle daily prior to the teriparatide treatment phase.
Finally, to confirm that the anticipated pharmacologic effects had occurred at the end of the 6-month treatment periods, 180 rats in 6 satellite groups of rats (n = 30 per group; not shown in Figure 1 ) were euthanized and evaluated at the end of the 6-month treatment period. The dosing regimen for these groups was identical to those for groups H5, H30, E5, and E30, except that animals were euthanized immediately after the teriparatide treatment period. Additional negative vehicle control groups were given once-daily injections of vehicle from 2-12 months and 2-8 months of age, respectively.
Dose Administration:
The dose formulation consisted of recombinant human PTH (1-34) (Eli Lilly and Company) in an aqueous vehicle of 20 mM sodium phosphate monobasic in 0.9% sodium chloride and 3 mg/ml of mannitol. Teriparatide doses of 5 or 30 µg/kg of body weight were administered by daily subcutaneous injection without anesthesia in the dorsal lumbar area. Throughout the treatment or pretreatment period, vehicle was administered according to the study design ( Figure 2 ). Doses were adjusted weekly for changes in body weight for the first 14 to 16 weeks, then every other week thereafter, replicating the procedure used in the first study.
Necropsy: All rats were necropsied, including those that died or were sacrificed in a moribund condition before the end of the study. Animals were anesthetized with isoflurane and euthanized by carbon dioxide asphyxiation. A complete gross examination was performed on each rat including a visual inspection and palpation of the axial and appendicular skeleton. In addition, there was a partial removal of overlying muscles of the vertebral column and limbs to facilitate the gross evaluation. Similar to the original carcinogenicity study, radiography was not performed. The femur, tibia, sternum, and lumbar vertebra were collected from each rat and preserved in 10% neutral buffered formalin. Femoral length was measured using calipers (Mitotoyo, Japan) and the wet weight of femora was measured with a Mettler balance. In addition, all gross lesions were collected and preserved in 10% neutral buffered formalin.
Quantitative Bone Analysis:
The femur and L-6 vertebra were excised, cleaned of soft tissue, and analyzed by quantitative computed tomography (QCT) (Sato et al., 1997) . The femoral midshaft was scanned along the transverse plane with a 960A pQCT loaded with Dichte software version 5.2 (Norland/Stratec, Ft Atkinson, Wisconsin), using pixels of 150 × 150 µm and slice thickness of 1,200 µm. The proximal tibial metaphysis were scanned along the transverse plane with a micro-XCT loaded with Dichte software version XCT540 (Norland/Stratec), using voxels of 70 × 70 × 150 µm. Parameters analyzed included volumetric bone Vol. 32, No. 4, 2004 DOSE AND DURATION EFFECTS OF rhPTH(1-34) 429 mineral density (BMD, mg/cc), cross-sectional area (X-Area, mm 2 ), and bone mineral content (BMC, mg) . Similarly, L-6 vertebrae were analyzed in cross-section with a micro-XCT (Norland/Stratec, Dichte software version XCT540), using voxels of 150 × 150 × 150 µm.
High-resolution images of the proximal femur were analyzed at a 23-µm resolution (isotropic) using an EVS mi-croCT (EVS Co, London, Ontario). Morphometric features of these images were analyzed histomorphometrically with a semi-automatic digitizing system (KSS Image Analysis, KSS Scientific Consultants, Magna UT) coupled to a Pow-erPC 7100/66 (Apple Computer, Cupertino, California), using the image capture functions of NIH Image 1.59 (NIH, Bethesda, Maryland) . Parameters analyzed included marrow area, cortical bone area, trabecular bone area, mean cortical thickness, trabecular number, and trabecular connectivity (total free-end-to-free-end struts, node-to-node struts) as described previously (Garrahan et al., 1986; Parfitt et al., 1987; Sato et al., 1997) .
Histopathology: Preserved specimens of femur, tibia, vertebra, sternum, and gross lesions were trimmed for histologic processing. For the bone specimens, 2 adjacent lumbar vertebra, 2 adjacent sternbrae, a longitudinal section of 1 femur that contained diaphysis and distal metaphysis and epiphysis, and a longitudinal section of 1 tibia that contained the diaphysis and proximal metaphysis and epiphysis were trimmed and placed in individual cassettes. These bone specimens, as well as any gross lesions that contained bone, were decalcified using a formic acid and hydrochloric acid solution (IMEB Inc., San Marcos, California). Tissues were processed through graded alcohol and clearing agent, infiltrated and embedded in paraffin, microtomed, and stained with hematoxylin and eosin.
The tissue sections were examined by light microscopy by a veterinary pathologist certified by the American College of Veterinary Pathologists. Following completion of the primary histopathology evaluation, a pathologist performed an independent peer review of all bone proliferative lesions. Proliferative lesions were classified according to criteria for rats published by the Society of Toxicologic Pathology (Long et al., 1993) , nomenclature for bone neoplasms of humans (Dorfman and Czerniak, 1998) , and criteria established by a pathology working group for the first rat carcinogenicity study with teriparatide .
Following histologic evaluation of hematoxylin and eosin stained sections, a subgroup of 8 representative osteosarcomas from the positive-control group (Figure 2 , group B30) was selected for immunohistochemical detection for PTH receptors. From each of the 8 neoplasms, additional unstained histologic sections were prepared. Following antigen retrieval in a citrate buffer, slides were immunostained on a Dako Automatic Immunostainer (Dako, Carpinteria, California) with a PTH receptor polyclonal antibody (Berkley Antibody Company, Richmond, California). Briefly, the PTHr antibody was incubated on the tissue sections overnight at a concentration of 10 micrograms/ml. After washing, the secondary antibody (Dako antirabbit) was incubated for 30 minutes. After washing, the labeled streptavidin-biotin complex, LSAB2 (Dako, Carpinteria, California), was incubated for 10 minutes. Slides were washed 5 minutes between each step with tris-buffered phosphate solution. The chromagen, diaminobenzidine tetrahydrochloride (DAB), was incubated on the slides for 5 minutes. Slides were gently counterstained with hematoxlyin and eosin and examined by light microscopy. Positive controls included osteoblasts within adjacent nonneoplastic bone as well as reference sections of a human prostate carcinoma that expresses the PTH receptor (Iddon et al., 2000) .
Modeling and Statistical Analyses: Clinically observed tumor incidence was analyzed using a nonlinear fixed effects model (Splus, version 2000, Insightful Corporation, Seattle, WA) . Mean ± standard errors are presented as indicated in specific figures and tables. QCT and histomorphometry data were evaluated by analysis of variance (ANOVA) with pairwise contrasts examined using Fisher's protected least significant difference (Fisher's PLSD) where the significance level for the overall ANOVA was p < 0.05 (StatView, Abacus Concepts, Berkeley, CA). Analyses on the proportions of animals that developed bone neoplasms were conducted at a significance level of 0.025 (Lin and Rahman, 1998) . The significance level of 0.025 was used because spontaneous bone neoplasms in rats are defined as rare, with a background incidence of <1% (Boorman et al., 1990) .
RESULTS
Modeling of Bone Tumor Incidence from the First Oncogenicity Study
Incidence of bone proliferative lesions observed during the live phase of the first oncogenicity study ) is plotted versus time for male and female F344 rats ( Figure 1 ). Clinical observance of bone tumor incidence in the initial rat study was found to fit an exponential equation, where tumor incidence F(x) = e A(X-Xo) with X as treatment duration, Xo as the lag phase before tumors were observed, and A as a coefficient. The exponential equation was observed to fit the bone tumor incidence with a correlation coefficient R 2 = 0.90-0.98 ( p < 0.0004). This equation permitted calculation of a lag phase Xo before observation of the first tumor, compared to the real Xo observed during actual live phase ( Figure 1 ). The calculated Xo and actual Xo tended to be lower for the 75 µg/kg group compared to the 5 µg/kg group. Relative to a female rat life span of 2 years, modeling showed that dosing of 5, 30, and 75 µg/kg required durations of approximately 82, 77, and 72% of lifetime, respectively, before bone tumors were clinically observed in F344 rats. Therefore, a substantial duration of treatment with respect to lifespan appeared to be required for teriparatide induction of bone tumors.
Pharmacodynamic Effects on Bone
Vertebra and femora from the second study ( Figure 2 ) were excised at necropsy and evaluated by QCT (Figures 3 and  4 , Table 1A ). Substantial increases in bone mass of 38% and 78% were observed for vertebra from animals treated with 5 or 30 µg/kg for 20 months from 6-26 months of age (groups I5, I30), respectively. Vertebra from the positive controls treated with 30 µg/kg teriparatide from 2-26 months of age (group B30) had bone mass that was 87% greater than vehicle controls ( for the 30 µg/kg dose group in the original 2-year rat study Vahle et al., 2002) . Marked increases in bone mass beyond normal animals were also observed after 20 (groups I5 and I30) months of teriparatide treatment (Figure 3 ).
Six months treatment: Rats necropsied after 6 months' treatment from 2 to 8 or 6 to 12 months of age showed marked skeletal increases at both cortical and trabecular sites. Compared to age-matched vehicle controls, substantial increases in bone mineral content (BMC 55-56%) and bone mineral density (BMD 34-39%) were observed for vertebra after 6 months treatment with 30 µg/kg. Similar increases in bone mass (BMC 34%, 39%) were observed for femora for animals treated from 2 to 8 or 6 to 12 months of age, respectively. These exaggerated pharmacodynamic effects were compara- ble to skeletal efficacy described previously for 6 months' PTH treatment (Sato et al., 1997 Kishi et al., 1998; Stewart et al., 2000) . Evaluation of vertebra for 26-month old rats showed that bone mass from rats withdrawn from treatment after 6 months of teriparatide administration (groups E5, E30, H5, H30) was similar to that from vehicle controls. These data showed that teriparatide skeletal efficacy in these animals did not persist following 14 (groups E5, E30) or 18 months (H5, H30) of treatment withdrawal. These findings taken together show that the increase in vertebral bone mass is treatment duration and dose dependent .
Effects on marrow area: Quantification of marrow area in the proximal femur confirmed a substantial reduction of 85% for the positive control (group B30) compared to the Vol. 32, No. 4, 2004 DOSE AND DURATION EFFECTS OF rhPTH(1-34) 431 Table 1 ). This magnitude of the observed teriparatide stimulation of endocortical mineral apposition, resulting in marrow occlusion was comparable to the middle dose group of the original 2- year rat study Vahle et al., 2002) . Marrow area was not different from vehicle controls for 26-monthold rats that were withdrawn from treatment after 6 months of teriparatide administration (groups E5, E30, H5, H30). Noticeable reductions in marrow area were observed for rats treated with teriparatide for 20 months (groups I5 and I30), compared to normal animals (vehicle controls) (Figures 4 and 5, Table 1 ). Marked alterations in bone mass and architecture were observed with long-term teriparatide treatment including substantial reduction in marrow spaces for groups B30, I5, and I30 as compared with vehicle control (A) (Figure 4) .
Marrow area was reduced by 73% and 87% for animals treated with 5 or 30 µg/kg for 20 months from 6-26 months of age, respectively. These data show marked skeletal effects for 5 and 30 µg/kg after 20 months in rats. The positive control (group B30) confirmed remarkable pharmacodynamic effects compared to normal rats (vehicle controls) for 30 µg/kg after 24 months' treatment. 
Incidence of Bone Neoplasms
No bone neoplasms were detected in groups examined after the 6-month treatment period, whether treated during the skeletal rapid growth phase between 2-8 months of age, or after the rapid growth phase between 6-12 months of age.
One rat in the vehicle control group (group A) developed a mass on the hind limb at approximately 20 months of age. Upon histologic examination, the mass was a high-grade oseosarcoma. The occurrence of a single osteosarcoma in the vehicle control group of 60 rats is consistent with the spontaneous occurrence rate of osteosarcoma (0.4%) in F344 rats (Haseman et al., 1998) .
Treatment with 30 µg/kg for 24 months (B30) or 20 months (I30) significantly increased the incidence of primary bone neoplasms ( Table 2 ). Most of these neoplasms were osteosarcomas, but there was also a low incidence of osteoma and osteoblastoma. The incidence of bone neoplasms was dependent on treatment duration, with the total incidence in rats treated for 24 months (B30) being double the total incidence in rats treated for 20 months (I30) (12/60 compared to 6/60, respectively). The incidence of bone neoplasms in rats treated for 24 months was very similar to the incidence that occurred in the original carcinogenicity study and indicated adequate replication of the conditions of the previous study . The initial occurrence of osteosarcoma occurred after approximately 18 months of treatment, as observed in the original study, Figure 1 . Importantly, no bone neoplasms were observed in the groups treated with 5 µg/kg starting at 6 months of age for 6 or 20 months (groups H5 and I5), as evaluated at study termination.
In 3 groups (H5, E30, H30), the incidence of bone tumors was not statistically different from the concurrent control group A. In rats treated with 5 µg/kg from 2 to 8 months of age and evaluated at 26 months of age (H5), there was a single osteosarcoma and a single osteoma. In rats treated with 30 µg/kg for 6 months and then removed from treatment (E30 and H30), there were 2 osteosarcomas in each group.
Gross and Histologic Features of Bone Neoplasms
The gross and histologic features of the neoplasms were similar to the findings observed in the original study (Table 3, . Most of the bone neoplasms (80%) were Vol. 32, No. 4, 2004 DOSE AND DURATION EFFECTS OF rhPTH(1-34) 433 Figures 6-11 . 32, No. 4, 2004 DOSE AND DURATION EFFECTS OF rhPTH(1-34) 435 observed grossly as nodules within or involving bones and involved only 1 bone site. The remaining bone neoplasms were not detected at gross examination and were small microscopic lesions within the histologic sections of bone. Osteosarcoma in multiple sites occurred in only 2 rats treated with 30 µg/kg daily for 24 months (B30). The most common site of occurrence for bone neoplasms was the vertebra, followed by the tibia, rib, and femur. The majority of the neoplasms were osteosarcomas and varied from low-grade lesions with minimal cytologic atypia ( Figures 6 and 7) to high-grade lesions, which were invasive, markedly anaplastic, and had limited amounts of matrix production (Figures 8 and 9 ). Osteoblastomas occurred at a low incidence and were similar in microscopic appearance to those first described in the rat in the original carcinogenicity study with teriparatide ( Figures 10  and 11) . Osteomas also occurred with a low incidence and were typical of those previously described . No positive staining for the PTH receptor was detected in the neoplastic cells in the subset of osteosarcomas (n = 8) from the positive control group B30 that were stained for the PTH1 receptor. Positive staining for the PTH receptor was observed in osteoblasts of the adjacent nonneoplastic bone and in the prostatic adenocarcinoma that served as a positive control.
Vol
Nonneoplastic Bone Changes
Nonneoplastic proliferative lesions were limited to small microscopic foci, which were not apparent at gross examination (Table 4 ). Similar to the initial carcinogenicity study, focal osteoblast hyperplasia was observed at a low incidence and consisted of focal increases in well differentiated, osteoblast-like cells with local osteoid production, but without significant disruption of preexisting bone trabeculae ( Figures 12 and 13) Vahle et al., 2002) . A histologic change diagnosed as focal stromal proliferation occurred at a low incidence and consisted of a focal proliferation of spindle-shaped stromal cells that filled marrow spaces with loose fibrous connective tissue and varying proportions of vascular components (Figures 14 and 15 ). Focal stromal proliferation was often associated with localized and limited resorption of trabecular bone and/or small foci of osteoid deposition, but had no dysplastic or anaplastic features of neoplasia.
Occasionally, the stromal proliferation had a more prominent vascular component and the lesion was recorded as "stromal vascular proliferation" (Figure 16 ). Focal stromal proliferation was not observed in the initial carcinogenicity study; however, rats in the current study were examined over a wider range of treatment durations. Similar to the first study, increases in trabecular bone were evident in light microscopic sections and were recorded as trabecular hypertrophy (Table 5 ). No significant effects on the incidence of tumors in nonosseous tissues were observed.
DISCUSSION
The first rat carcinogenicity study with teriparatide had several design features that differed substantially from the intended clinical use, resulting in questions regarding the relevance of the rat carcinogenicity data to human risk assessment. Two of the several design features that were potentially important included initiation of treatment during rapid skeletal growth and treatment for a large proportion of the rat's lifespan. The purpose of the current study was to examine in greater detail the importance of dose, duration of treatment and age at initiation of treatment on the development of bone tumors in rats treated with teriparatide.
The effects of teriparatide on bone mass at the end of the 6-, 20-, and 24-month treatment periods were both time and dosedependent and were consistent with the results of prior studies (Sato et al., 1997 (Sato et al., , 2000 Vahle et al., 2002) . Treatment of female rats for 6 months caused marked increases in bone mass at both cortical and trabecular locations (Kishi et al., 1998; Stewart et al., 2000; Sato et al., 2002) . In ovariectomized rats (Sato et al., 1997) , a 6-month duration of treatment at 8 µg/kg resulted in elevated bone mass for the axial and appendicular skeleton that was greater than levels observed for normal rats (sham-ovariectomy controls). Similar data were obtained for 5-40 µg/kg PTH (Kimmel et al., 1993; Stanislaus et al., 2000) indicating that Sprague-Dawley, Wistar, and F344 rat skeletons are highly responsive to PTH. Therefore, the collective data show that treatment of rats with 30 µg/kg for as little 436 VAHLE ET AL.
TOXICOLOGIC PATHOLOGY as 6 months resulted in marked pharmacodynamic effects compared with normal animals (including sham-ovariectomy controls) (Sato et al., 1997 Kishi et al., 1998; Stewart et al., 2000) . Consistent with the results of the original carcinogenicity study , rats treated with 30 µg/kg for 24 months had highly exaggerated increases in bone mass, resulting in large diminution of marrow area. Similar exaggerated effects on bone mass and elimination of marrow area were also observed in rats given 30 µg/kg for 20 months. In total, the effects on bone mass across the 6-, 20-, and 24-month treatment periods confirm that the pharmacodynamic effects in the current study were dependent on both the administered dose and duration of treatment. These results also demonstrate that the rat skeleton is unusually responsive to the anabolic effect of PTH, in comparison with nonhuman primates and humans (Tashjian and Chabner, 2002) .
Similar to the pharmacodynamic effects on the skeleton just discussed, teriparatide effects on bone tumor incidence were clearly dependent on duration of treatment and dose. An unequivocal increase in bone tumor incidence occurred only after an extended duration of treatment (20 or 24 months) at the highest dose level of teriparatide (30 µg/kg). These groups (B and I30) also had the most profound increases in bone mass for the longest period of time. Importantly, no bone neoplasms occurred in rats treated with 5 µg/kg from 6 to 12 or 6 to 26 months of age. Results from these two groups establish a treatment regimen in rats that produces substantial increases in bone mass, but does not increase the incidence of bone neoplasia. Cumulatively, these data demonstrate that there is a threshold for the development of bone neoplasms in the rat based on treatment duration and dose, and that this threshold is greater than the threshold required to produce the desired pharmacologic effect on bone, especially in primates (Tashjian and Chabner, 2002) .
These findings are consistent with the hypothesis generated from the first study that the teriparatide-induced bone neoplasms in rats are secondary to long-term hormonal stimulation (Whitfield, 2001; Tashjian and Chabner, 2002) . In assessing the human hazards of nongenotoxic carcinogens, Silva and Van der Laan (2000) point out that the tumorigenic response will not occur up to a certain defined threshold, particularly for drugs acting through a receptor-mediated mechanism. Understanding these relationships is useful because it confirms the importance of accounting for differences in the treatment duration, based on percentage of life span, between rats and humans in assessing the clinical relevance of the findings in rats. In addition to confirming that duration of treatment is an important factor in the development of bone neoplasms in the rat, these results also demonstrated that treatment early in life is not required to induce bone proliferative lesions in the rat. The finding that treatment with 30 µg/kg, beginning at 6 months of age and continuing to 26 months of age, resulted in a clear increase in bone tumor incidence supports this supposition. The numerical difference in bone tumor incidence in rats given teriparatide from 2 to 26 versus 6 to 26 months of age might suggest a minor role of age at initiation of treatment. However, because rats that started treatment at 6 months of age had a comparatively reduced duration of treatment, duration is more likely to account for the apparent difference in bone tumors response due to the observed exponential relationship between tumor number and duration beyond a lag phase. Overall, these results indicate that any effect of age at initiation of treatment has a minor role, if any, in comparison to the effects of duration and dose of treatment.
In contrast to the clear effects described previously, it is difficult to interpret the low incidence of bone neoplasms in groups given 5 or 30 µg/kg from 2 to 8 months or given 30 µg/kg from 6 to 12 months. Two rats in each of these groups had bone neoplasms. This incidence was not statistically different from controls, and is also similar to the published historical control study ranges (0-2%, 0.4% overall) for osteosarcoma in F344 rats (Haseman et al., 1998) . While it is not possible to draw definitive conclusions from the results of these groups, they are consistent with the results of the other arms in demonstrating that a reduced duration of treatment significantly reduced the incidence of bone neoplasms.
In addition to the bone neoplasms, nonneoplastic bone proliferative lesions were observed in treated rats. Similar to the original carcinogenicity study, focal osteoblast hyperplasia occurred at a low incidence. The histologic change described as focal stromal proliferation had not been observed in the previous study and was most prominent in rats treated with 30 µg/kg from 6 to 26 months of age that also had prominent trabecular hypertrophy. Similar changes were not seen in rats evaluated at the end of the 6-month treatment period. Although the histologic origin of this lesion was not determined, the stromal cells were presumed to include osteoprogenitor cells. Based on the histomorphology of these lesions, we cannot rule out that focal osteoblast hyperplasia and focal stromal proliferation could represent early proliferative lesions of osteoprogenitor cells; however, focal stromal proliferation did occur in groups that did not have an increased incidence of osteosarcoma and a low number of osteosarcomas (2) were observed in a group which did not have evidence of focal stromal proliferation. As such, it was not clear that these changes are part of a neoplastic continuum. Because these were small focal lesions, the incidence reflects those lesions detected in the panel of bones processed for histologic evaluation. Despite the uncertainty regarding the relationship of these nonneoplastic lesions to the neoplastic lesions of bone, the incidence of both groups of lesions were dependent on dose and duration of treatment.
Previously, rats were administered up to 1 mg/kg PTH for up to 1-month duration without any diminution of anabolic skeletal activity or substantial impairment of bone quality as assessed by histomorphometry (Jerome, 1994) . Therefore, rats, unlike humans, are able to tolerate and respond to chronic subcutaneous administration of massive doses of PTH. Our modeling showed that clinical observation of bone neoplasia is preceded by a considerable lag phase of 524 to 639 days (17.5-21 months, or 72-82% of lifetime) for 75 to 5 µg/kg teriparatide in female rats. Jerome (1994) noted that there is an upper limit to the increase in bone mass achievable in female rats, but the maximum bone mass can be reached more rapidly with higher doses of PTH. An actual leveling off of bone efficacy (BMD) was described in the first study (Sato et al., 1997) as marrow spaces were replaced by bone. A previous 1-year rat study showed that substantial reductions in marrow spaces occur after about 1-year with 8 to 40 µg/kg Vol. 32, No. 4, 2004 DOSE AND DURATION EFFECTS OF rhPTH(1-34) 437 teriparatide (Sato et al., 1997) . Therefore, the cumulative rat data suggest that substantial reductions in marrow space precede the manifestation of bone neoplasia for 5 to 75 µg/kg teriparatide.
CONCLUSIONS Results from the first and present study clearly demonstrated that the pharmacodynamic effects of teriparatide and the incidence of bone neoplasms in rats are both dependent on dose and duration of treatment. In addition, treatment early in life is not required for the induction of bone neoplasms in rats by teriparatide, provided that administration is of sufficient duration. Importantly, this study demonstrated that an exaggerated pharmacodynamic effect could be induced in the rat for a combination of dose and treatment duration that does not induce bone neoplasia. Because teriparatide is currently utilized to treat postmenopausal women with osteoporosis, it is rational to compare the treatment regimens between the rat studies and human clinical use. Based on data (area under the concentration curve) from the previous carcinogenicity study, serum exposures to teriparatide in rats given 5 µg/kg was approximately 3-fold greater than in women given a 20 µg dose of teriparatide (Tashjian and Chabner, 2002) . At this level of exposure, rats could be treated for 20 months, or approximately 70% of their life span, without developing bone neoplasms. This is in sharp contrast to the relatively short duration of treatment patients will receive (approximately 2 years or 2-3% of life span). These results are consistent with the conclusions that the bone tumors in rats are not likely to be predictive of an increased risk of bone tumors in humans relative to the proposed clinical dose and duration of treatment (Rubin et al., 2002; Tashjian and Chabner, 2002) .
